Table 8.
Effect of setup and range uncertainties on CTV2_Pro+proxSVs in phase 2 PBS plans.
| Setup/range errors | CTV2_Pro+proxSVs |
||||
|---|---|---|---|---|---|
| D98% (Gy(RBE)) | V45Gy(RBE) (%) | D2% (Gy(RBE)) | HI2–98% | ||
| Setup: A-P | +3 mm | 34.35 ± 0.13 | 99.39 ± 1.06 | 35.25 ± 0.23 | 0.02 ± 0.01 |
| y | +5 mm | 34.21 ± 0.13* | 97.49 ± 3.12 | 35.34 ± 0.22 | 0.02 ± 0.01 |
| −3 mm | 34.39 ± 0.12 | 99.49 ± 0.82 | 35.33 ± 0.20 | 0.02 ± 0.01 | |
| −5 mm | 34.31 ± 0.13 | 98.93 ± 1.25 | 35.47 ± 0.14 | 0.03 ± 0.01 | |
| Setup: S-I | +3 mm | 34.41 ± 0.12 | 99.78 ± 0.36 | 35.23 ± 0.20 | 0.02 ± 0.01 |
| z | +5 mm | 34.33 ± 0.11 | 99.21 ± 0.83 | 35.35 ± 0.16 | 0.02 ± 0.01 |
| −3 mm | 34.41 ± 0.14 | 99.65 ± 0.66 | 35.29 ± 0.25 | 0.02 ± 0.01 | |
| −5 mm | 34.33 ± 0.15 | 99.02 ± 1.36 | 35.38 ± 0.28 | 0.02 ± 0.01 | |
| Setup: L-R | +3 mm | 34.45 ± 0.14 | 99.87 ± 0.21 | 35.21 ± 0.23 | 0.02 ± 0.01 |
| x | +5 mm | 34.44 ± 0.14 | 99.87 ± 0.18 | 35.18 ± 0.15 | 0.02 ± 0.01 |
| −3 mm | 34.45 ± 0.14 | 99.85 ± 0.30 | 35.21 ± 0.25 | 0.02 ± 0.01 | |
| −5 mm | 34.45 ± 0.14 | 99.82 ± 0.33 | 35.21 ± 0.24 | 0.02 ± 0.01 | |
| Range (HU) | +3.5% | 34.71 ± 0.11* | 100.00 ± 0.00 | 35.38 ± 0.18 | 0.01 ± 0.01 |
| −3.5% | 34.31 ± 0.12 | 98.54 ± 2.60 | 35.01 ± 0.21 | 0.02 ± 0.01 | |
CTV, clinical target volume; Gy(RBE); gray(radiobiological equivalent); Pro + proSVs, prostate and proximal seminal vesicles, Dx, dose received by the target at a defined volume (x) in percentage; Vx, volume of the target receiving x dose in Gray; HI, homogeneity index; HU, hounsfield units; A-P, anterior-posterior; S-I, superior-inferior; L-R, left-right; *p < 0.05, statistically significant.